{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:29:26Z","timestamp":1791595766488,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msard.2020.102696","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T01:29:27Z","timestamp":1608168567000},"page":"102696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7572-3615","authenticated-orcid":false,"given":"Paul M.","family":"Elsbernd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-8980","authenticated-orcid":false,"given":"William R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8206","authenticated-orcid":false,"given":"Dean M.","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102696_bib0001","first-page":"e1858","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90.21","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33.1","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2020.102696_bib0003","first-page":"1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13.1","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102696_bib0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13.1","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102696_bib0005","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140.12","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102696_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19.3","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102696_bib0007","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53.5","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0008","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult. Scler. Related Disord."},{"key":"10.1016\/j.msard.2020.102696_bib0009","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21.7","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102696_bib0010","first-page":"e111","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95.2","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0011","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89.2","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102696_bib0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15.4","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2020.102696_bib0013","first-page":"1280","article-title":"Neurological update: MOG antibody disease","volume":"266.5","author":"Ray","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102696_bib0014","first-page":"1005","article-title":"Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production","volume":"114.5","author":"Fang","year":"2009","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.msard.2020.102696_bib0015","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1212\/01.WNL.0000148481.80152.BF","article-title":"Activation of humoral immunity and eosinophils in neuromyelitis optica","volume":"63.12","author":"Correale","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0016","article-title":"Effects of neuromyelitis optica\u2013IgG at the blood\u2013brain barrier in vitro","volume":"4.1","author":"Takeshita","year":"2017","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102696_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17.6","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.msard.2020.102696_bib0018","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/conmed-2018-000005","article-title":"Interleukin 6: the biology behind the therapy","volume":"2.1","author":"Jones","year":"2018","journal-title":"Considerations Med."},{"key":"10.1016\/j.msard.2020.102696_bib0019","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74.6","author":"Brunner","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2020.102696_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/08830185.2014.938325","article-title":"Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights","volume":"34.3","author":"Hashizume","year":"2015","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.msard.2020.102696_bib0021","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23.8","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.msard.2020.102696_bib0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377.4","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102696_bib0023","doi-asserted-by":"crossref","unstructured":"Nishimoto, Norihiro, et\u00a0al. \"A long-term (5-Year) sustained efficacy of tocilizumab for multicentric Castleman's disease and the effect on pulmonary complications.\" (2007): 646-646.","DOI":"10.1182\/blood.V110.11.646.646"},{"key":"10.1016\/j.msard.2020.102696_bib0024","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.autrev.2017.08.002","article-title":"Targeting interleukin-6 in autoimmune uveitis","volume":"16.10","author":"Mesquida","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2020.102696_bib0025","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7.5","author":"Fujihara","year":"2020","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102696_bib0026","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2.4","author":"Melamed","year":"2015","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102696_bib0027","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16.12","author":"Uzawa","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102696_bib0028","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83.3","author":"Uzawa","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102696_bib0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2020.102696_bib0030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti\u2013IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82.15","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0031","article-title":"Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab","volume":"2014","author":"Lauenstein","year":"2014","journal-title":"Case Rep."},{"key":"10.1016\/j.msard.2020.102696_bib0032","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jns.2019.10.1108","article-title":"Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study","volume":"405","author":"Traboulsee","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102696_bib0033","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381.22","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102696_bib0034","doi-asserted-by":"crossref","unstructured":"Takai, Yoshiki, et\u00a0al. \"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.\" Brain 143.5 (2020): 1431-1446.","DOI":"10.1093\/brain\/awaa102"},{"key":"10.1016\/j.msard.2020.102696_bib0035","first-page":"1","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.msard.2020.102696_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01188","article-title":"Comparative analysis of T-cell responses to aquaporin-4 and myelin oligodendrocyte glycoprotein in inflammatory demyelinating central nervous system diseases","volume":"11","author":"Hofer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2020.102696_bib0037","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.23621","article-title":"Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate","volume":"72.3","author":"Br\u00fcck","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102696_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577361","article-title":"Serum level of IL-1\u03b2 in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)","author":"Kwon","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102696_bib0039","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89.9","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102696_bib0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82.6","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0041","article-title":"Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Related Disord."},{"key":"10.1016\/j.msard.2020.102696_bib0042","first-page":"765","article-title":"Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis","volume":"92.16","author":"Helen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102696_bib0043","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.msard.2018.11.012","article-title":"Tocilizumab in MOG-antibody spectrum disorder: a case report","volume":"27","author":"Novi","year":"2019","journal-title":"Mult. Scler. Related Disord."},{"key":"10.1016\/j.msard.2020.102696_bib0044","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"Lotan","year":"2020","journal-title":"Mult. Scler. Related Disord."},{"key":"10.1016\/j.msard.2020.102696_bib0045","article-title":"Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment","volume":"46","author":"Masuccio","year":"2020","journal-title":"Mult. Scler. Related Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:02Z","timestamp":1761900722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"alternative-id":["S2211034820307707"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102696","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102696"}}